Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca teams with Heptares

AstraZeneca has teamed up with UK-based drug discovery company Heptares in a four-year collaboration to develop new therapies that target proteins linked to nervous system and cardiovascular disorders

AstraZeneca (AZ) has teamed up with UK-based drug discovery company Heptares in a four-year collaboration to develop new therapies that target proteins linked to nervous system and cardiovascular disorders.

The deal includes a £3.8m payment to Heptares, which will also be eligible for royalties from any successful products, while AZ will gain the worldwide rights.

The collaboration will make use of Heptares' G protein-coupled receptors (GPCR) discovery expertise and proprietary technologies - including its StaR technology, which engineers stabilised receptors allowing GPCRs to be investigated.

GPCRs are one of the largest family of proteins, yet have an inherent instability when removed from cell membranes, according to a statement from AZ. 

Research conducted under the collaboration will focus on a number of specific GPCR targets linked to central nervous system/pain, cardiovascular/metabolic and inflammatory disorders from projects in AZ's small and large molecule portfolio, including projects from AZ's biologics unit, MedImmune.

Martin Mackay, president of research and development, AZ, said: "Our work will focus on a range of different diseases across our small and large molecule portfolio with the goal of discovering innovative treatments for patients in areas of medical need."

31st May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

The Heart of the Matter 9: Context is King
McCann Complete Medical outlines why multichannel communications - anchored in strong clinical data from journal publications - must not only be transparent, they must also provide a clear clinical context...
Cell and gene therapies: on course for commercial success?
...
eyeforpharma_h_logo.png
Make Anthill your strategic partner in Barcelona
We are excited to attend and exhibit at eyeforpharma Barcelona 2017 (March 14-16th), and present two multichannel strategy workshops....

Infographics